Tuesday, February 28, 2006

The Ludwig von Mises Institute

The Ludwig von Mises Institute "was founded in 1982 as the research and educational center of classical liberalism, libertarian political theory, and the Austrian School of economics. It serves as the world's leading provider of educational materials, conferences, media, and literature in support of the tradition of thought represented by Ludwig von Mises and the school of thought he enlivened and carried forward during the 20th century, which has now blossomed into a massive international movement of students, professors, professionals, and people in all walks of life. It seeks a radical shift in the intellectual climate as the foundation for a renewal of the free and prosperous commonwealth."

Liberty and Economics - a 38-minute YouTube video from the Ludwig von MIses Institute that espouses the virtues of free markets and capitalism.

Friday, November 18, 2005

Research Dispels Bush Claims That Tax Cuts Create Jobs

In the November 18, 2005 OneWorld.net article "Research Dispels Bush Claims That Tax Cuts Create Jobs," Haider Rizvi explains:
Changes in tax policy suggest no evidence of their impact on job creation or destruction, according to the 22-page study released Tuesday by United for a Fair Economy (UFE), an independent group that tracks the growing economic divide between the nation's haves and have-nots.

Since 1950, significant tax increases and decreases have both been followed by job losses and job gains, say the researchers.

Based on statistical analysis of changes in tax polices and rates of job growth in the past 60 years, the report points out that tax reduction does, however, disproportionately lead to economic disparity between the rich and poor.

Tuesday, September 20, 2005

Cost of Katrina relief splits Republican ranks

In the September 20, 2005 Christian Science Monitor article "Cost of Katrina relief splits Republican ranks," Gail Russell Chaddock reports on the conflicts between Republican philosphy and reality.

President Bush's call to spend "whatever it takes" to rebuild the Gulf Coast set off alarm bells among some in his conservative base - and stepped up a growing debate among Republicans at both ends of Pennsylvania Avenue on how to fix the battered region in ways that promote conservative values.

From vouchers for education and Medicaid to the creation of a giant "opportunity zone" where Katrina struck, the Bush reconstruction effort - which he called "one of the largest reconstruction efforts the world has ever seen" - is reviving prospects for policy initiatives that GOP leaders say could make or break their party's future.

At the same time, fiscal conservatives, often outside of leadership, are calling for deep cuts in existing spending to pay the costs of reconstruction. They, too, see this as a fight for the soul of the Republican Party.

"It's too early to tell. It could wind up being the New Deal on steroids," says Mike Franc, vice president for governmental affairs at the Heritage Foundation, a conservative think tank.

For a president who campaigned on Ronald Reagan's legacy of limited government, the vast scope of needs in the region pose a special
challenge. While President Roosevelt's New Deal and President Johnson's War on
Poverty offer templates for a federal response, Republicans have campaigned for
decades to roll them back.

"If people can agree that the last 40 years didn't help win the War on Poverty in New Orleans and the Gulf - and even hurt it - then the debate shifts into not replicating the last 40 years," says Mr. Franc.

But if the congressional committees bog down and can't agree on a package of reforms that can be financed without breaking the bank, "the default could be going with what we already have," he adds.

In recent weeks, Republican leaders have tasked every committee in Congress to come up quickly with new ideas that meet needs in the region.

These range from a vast package of tax breaks to revive business and housing in the Gulf, to Education Smart cards, which give families the option of paying for education wherever it is available and suits their needs, including private and parochial schools.

But to move such a plan, Republicans will need coherence in their own ranks, especially agreement across their caucus on how to pay for it. For fiscal conservatives, the biggest issue in the Gulf cleanup is its price tag, expected to exceed $200 billion. Congress has already appropriated $62 billion in emergency spending..

"Congress must ensure that a catastrophe of nature does not become a catastrophe of debt for our children and grandchildren," says Rep. Mike Pence(R) of Indiana, who chairs the Republican Study Group, a top conservative caucus.

The Heritage Foundation estimates that such levels of spending could bump budget deficits past $500 billion in 2008 to $873 billion in 2015.

In response, some conservative lawmakers are calling on their leaders to find offsets for new spending, including delaying implementing the new Medicare drug benefit, rolling back pork projects in recently passed Highway and Energy bills, and even
deferring a vote on the permanent extension of Bush tax cuts. Last week, 11 House Republicans voted against a $52 billion hurricane relief bill in protest
against the failure to identify offsets.

In a comment to reporters last week, House majority leader Tom DeLay said that after 11 years of a Republican majority, there wasn't much fat to cut in the federal budget.

The comment alarmed many conservative activists outside
government who see the big spending ways of the Bush administration as a betrayal of small- government ideals.

"I have to pretty strongly disagree with the majority leader," says former GOP Rep. Pat Toomey, now head of the Club for Growth, an antitax group that backs Republican
candidates.

"Whatever money gets spent on this reconstruction effort really needs to be offset by reductions somewhere else," he adds. "It's not the role of the federal government to be rebuilding houses and strip malls...."

At a closed leadership meeting on Thursday, House GOP leaders tried to bridge divisions in their caucus by promising strong accountability on where new federal dollars are going "Whatever is expended by Congress, we want to make sure it is funded appropriately and that states and local communities, as well as the private sector, share the burden," said a House leadership aide.

While Republicans have stood by the president as he expanded the role of government in local schools and the war on terrorism, the new wave of post-Katrina spending could break that consensus at a time when the Bush's job rating is at record lows.

The bid to work conservative programs, such as education vouchers, into Gulf aid could help bridge those gaps.

"It's window dressing for the benefit of social conservatives," says Ross Baker, a
political scientist at Rutgers University in New Brunswick, N.J.. "The president may feel that whatever support he will lose among fiscal conservatives, he will win from conservatives proud of him for bootlegging vouchers in the relief plan."

Source: http://news.yahoo.com/s/csm/20050920/ts_csm/afiscal_1

Police Officers Advocate Legalized Regulation of all Drugs

Law Enforcement Against Prohibition (LEAP) is an organization dedicated to the legalization and regulation of all drugs. According to the advocacy group's website:

Founded on March 16, 2002, LEAP is made up of current and former members of the law enforcement and criminal justice communities who are speaking out about the failures of our existing drug policies. Those policies have failed, and continue to fail, to effectively address the problems of drug abuse, especially the problems of juvenile drug use, the problems of addiction, and the problems of crime caused by the existence of a criminal black market in drugs.

Although those who speak publicly for LEAP are people from the law enforcement and criminal justice communities, a large number of our supporting members do not have such experience. You don't have to have law enforcement experience to join us.

By continuing to fight the so-called "War on Drugs", the US government has worsened these problems of society instead of alleviating them. A system of regulation and control of these substances (by the government, replacing the current system of control by the black market) would be a less harmful, less costly, more ethical and more effective public policy.

Wednesday, September 1, 2004

Fox News responds to charges of bias

In the September 1, 2004 USA Today article "Fox newspeople say allegations of bias unfounded," Mark Memmott provides responses from Fox New reporters to allegations that the network has a conservative bias.
NEW YORK — The pundits were merciless.

President Bush's twins daughters, Barbara and Jenna, "came off, frankly, as ditzes" when they spoke to the Republican National Convention, one commentator said.

Laura Bush's speech "did not help" the president's campaign, said another.

The first lady and her daughters "had no place up there" on the convention stage, said a third.

It wasn't the liberal Air America radio network doing that skewering Tuesday night at the Republican convention.

The setting was Fox News Channel's skybox inside Madison Square Garden. The show was Special Report, moderated by Brit Hume. Morton Kondracke, executive editor of Roll Call, dissed the twins. William Kristol, editor of The Weekly Standard, gave Laura Bush's speech a low rating. Fred Barnes, executive editor of The Weekly Standard, thought the women shouldn't have been addressing delegates because "we're not electing a family."

All three are known for their conservative or independent political views. Their comments couldn't have been more opposite what conventional wisdom would predict a Fox News panel would say.

Fox News, its critics say, is a cheering squad for Republicans and the Bush administration. The network is the most visible American arm of Rupert Murdoch's News Corp. global media empire, which also includes the New York Post.

Fox's critics are counting the number of minutes the network devotes to speeches at this week's Republican convention compared with its coverage of the Democratic convention in July. The first two nights here: 2 hours and 9 minutes. The first two nights at the Democratic convention: 1 hour and 46 minutes. One reason for the difference: former New York City mayor Rudy Giuliani went overtime Monday.

A documentary released this summer, Outfoxed, shows former Fox staffers accusing their old bosses of ordering them to slant the news in favor of conservatives. And Tuesday outside Fox News' studios in Manhattan, protesters held a "Shut Up!" rally to express their anger at what they see as the network's conservative bias.

The people at Fox News see things differently. While the hosts who are paid to give their opinions make no attempts to hide their politics, the reporters and anchors on the news programs say they're traditional journalists who don't buy into attempts to spin the news:

• "The only marching order I've had is to do the best news show I can, and there's never been a single eyebrow raised (from management) about what we've done," says Chris Wallace, who joined Fox in 2003 after 15 years with ABC. He hosts Fox News Sunday with Chris Wallace.

• "The only time in my career that anyone ever told me I had to say something was when I was with a different organization," says senior White House correspondent Jim Angle, who worked at ABC for three years and National Public Radio for nine years before joining Fox in 1996.

• "I swear I'm not biased, and I know that no one (at Fox) has ever told me what to say," Fox Report anchor Shepard Smith says.

Bill O'Reilly, host of The O'Reilly Factor, is the lightning rod who catches many of the charges hurled at Fox News. He dismisses allegations that he sometimes makes up things to support his opinions and that Fox News is too conservative.

"If Fox News is a conservative channel — and I'm going to use the word 'if' — so what?" O'Reilly said Tuesday night as he removed his makeup following a broadcast of The O'Reilly Factor from inside Fox's skybox in Madison Square Garden. "You've got 50 other media that are blatantly left. Now, I don't think Fox is a conservative channel. I think it's a traditional channel. There's a difference. We are willing to hear points of view that you'll never hear on ABC, CBS or NBC."

Some critics say Fox and other cable networks overplayed the story of the veterans who accuse Sen. John Kerry of lying about his war record — and gave too much attention to the Swift Boat Veterans for Truth group even after some of its claims had been contradicted.

But Hume, who's been with Fox News since its beginning in 1996, said Fox took the story seriously because "you had Vietnam veterans, on the record, who were there and who were making serious allegations. How can you not do that story?"

Tom Rosenstiel, director of Columbia University's Project for Excellence in Journalism, warns of the "Foxification" of cable news. He says Fox News' ratings success — it attracted more convention viewers Tuesday than MSNBC and CNN combined — is pushing the other cable channels to be more like it by cutting back on news and adding more conservative opinion.

Even some who say Fox News gives them a fair shot at expressing their liberal opinions question the network's objectivity. A lion of the Democrats' liberal wing, Rep. Charles Rangel of New York, was on the Hannity & Colmes show Tuesday. Afterward, he made no effort to hide his feelings. "I go on Fox because a lot of Democrats won't," Rangel said. "Listen to me, Fox is not conservative. They're an extension of the Republican Party. Do they give me a fair shot when I'm on? Yes, because they need me. I'm red meat for their listeners."

Thursday, July 15, 2004

The Truth About Drug Companies

The New York Review of Books
Volume 51, Number 12 · July 15, 2004
The Truth About the Drug Companies

By Marcia Angell
1.

Every day Americans are subjected to a barrage of advertising by the pharmaceutical industry. Mixed in with the pitches for a particular drug—usually featuring beautiful people enjoying themselves in the great outdoors—is a more general message. Boiled down to its essentials, it is this: "Yes, prescription drugs are expensive, but that shows how valuable they are. Besides, our research and development costs are enormous, and we need to cover them somehow. As 'research-based' companies, we turn out a steady stream of innovative medicines that lengthen life, enhance its quality, and avert more expensive medical care. You are the beneficiaries of this ongoing achievement of the American free enterprise system, so be grateful, quit whining, and pay up." More prosaically, what the industry is saying is that you get what you pay for.

Is any of this true? Well, the first part certainly is. Prescription drug costs are indeed high—and rising fast. Americans now spend a staggering $200 billion a year on prescription drugs, and that figure is growing at a rate of about 12 percent a year (down from a high of 18 percent in 1999).[1] Drugs are the fastest-growing part of the health care bill—which itself is rising at an alarming rate. The increase in drug spending reflects, in almost equal parts, the facts that people are taking a lot more drugs than they used to, that those drugs are more likely to be expensive new ones instead of older, cheaper ones, and that the prices of the most heavily prescribed drugs are routinely jacked up, sometimes several times a year.


Before its patent ran out, for example, the price of Schering-Plough's top-selling allergy pill, Claritin, was raised thirteen times over five years, for a cumulative increase of more than 50 percent—over four times the rate of general inflation.[2] As a spokeswoman for one company explained, "Price increases are not uncommon in the industry and this allows us to be able to invest in R&D."[3] In 2002, the average price of the fifty drugs most used by senior citizens was nearly $1,500 for a year's supply. (Pricing varies greatly, but this refers to what the companies call the average wholesale price, which is usually pretty close to what an individual without insurance pays at the pharmacy.)

aying for prescription drugs is no longer a problem just for poor people. As the economy continues to struggle, health insurance is shrinking. Employers are requiring workers to pay more of the costs themselves, and many businesses are dropping health benefits altogether. Since prescription drug costs are rising so fast, payers are particularly eager to get out from under them by shifting costs to individuals. The result is that more people have to pay a greater fraction of their drug bills out of pocket. And that packs a wallop.

Many of them simply can't do it. They trade off drugs against home heating or food. Some people try to string out their drugs by taking them less often than prescribed, or sharing them with a spouse. Others, too embarrassed to admit that they can't afford to pay for drugs, leave their doctors' offices with prescriptions in hand but don't have them filled. Not only do these patients go without needed treatment but their doctors sometimes wrongly conclude that the drugs they prescribed haven't worked and prescribe yet others—thus compounding the problem.

The people hurting most are the elderly. When Medicare was enacted in 1965, people took far fewer prescription drugs and they were cheap. For that reason, no one thought it necessary to include an outpatient prescription drug benefit in the program. In those days, senior citizens could generally afford to buy whatever drugs they needed out of pocket. Approximately half to two thirds of the elderly have supplementary insurance that partly covers prescription drugs, but that percentage is dropping as employers and insurers decide it is a losing proposition for them. At the end of 2003, Congress passed a Medicare reform bill that included a prescription drug benefit scheduled to begin in 2006, but as we shall see later, its benefits are inadequate to begin with and will quickly be overtaken by rising prices and administrative costs.

For obvious reasons, the elderly tend to need more prescription drugs than younger people—mainly for chronic conditions like arthritis, diabetes, high blood pressure, and elevated cholesterol. In 2001, nearly one in four seniors reported that they skipped doses or did not fill prescriptions because of the cost. (That fraction is almost certainly higher now.) Sadly, the frailest are the least likely to have supplementary insurance. At an average cost of $1,500 a year for each drug, someone without supplementary insurance who takes six different prescription drugs—and this is not rare—would have to spend $9,000 out of pocket. Not many among the old and frail have such deep pockets.

Furthermore, in one of the more perverse of the pharmaceutical industry's practices, prices are much higher for precisely the people who most need the drugs and can least afford them. The industry charges Medicare recipients without supplementary insurance much more than it does favored customers, such as large HMOs or the Veterans Affairs (VA) system. Because the latter buy in bulk, they can bargain for steep discounts or rebates. People without insurance have no bargaining power; and so they pay the highest prices.

n the past two years, we have started to see, for the first time, the beginnings of public resistance to rapacious pricing and other dubious practices of the pharmaceutical industry. It is mainly because of this resistance that drug companies are now blanketing us with public relations messages. And the magic words, repeated over and over like an incantation, are research, innovation, and American. Research. Innovation. American. It makes a great story.

But while the rhetoric is stirring, it has very little to do with reality. First, research and development (R&D) is a relatively small part of the budgets of the big drug companies—dwarfed by their vast expenditures on marketing and administration, and smaller even than profits. In fact, year after year, for over two decades, this industry has been far and away the most profitable in the United States. (In 2003, for the first time, the industry lost its first-place position, coming in third, behind "mining, crude oil production," and "commercial banks.") The prices drug companies charge have little relationship to the costs of making the drugs and could be cut dramatically without coming anywhere close to threatening R&D.

Second, the pharmaceutical industry is not especially innovative. As hard as it is to believe, only a handful of truly important drugs have been brought to market in recent years, and they were mostly based on taxpayer-funded research at academic institutions, small biotechnology companies, or the National Institutes of Health (NIH). The great majority of "new" drugs are not new at all but merely variations of older drugs already on the market. These are called "me-too" drugs. The idea is to grab a share of an established, lucrative market by producing something very similar to a top-selling drug. For instance, we now have six statins (Mevacor, Lipitor, Zocor, Pravachol, Lescol, and the newest, Crestor) on the market to lower cholesterol, all variants of the first. As Dr. Sharon Levine, associate executive director of the Kaiser Permanente Medical Group, put it,

If I'm a manufacturer and I can change one molecule and get another twenty years of patent rights, and convince physicians to prescribe and consumers to demand the next form of Prilosec, or weekly Prozac instead of daily Prozac, just as my patent expires, then why would I be spending money on a lot less certain endeavor, which is looking for brand-new drugs?[4]
Third, the industry is hardly a model of American free enterprise. To be sure, it is free to decide which drugs to develop (me-too drugs instead of innovative ones, for instance), and it is free to price them as high as the traffic will bear, but it is utterly dependent on government-granted monopolies—in the form of patents and Food and Drug Administration (FDA)–approved exclusive marketing rights. If it is not particularly innovative in discovering new drugs, it is highly innovative—and aggressive—in dreaming up ways to extend its monopoly rights.

And there is nothing peculiarly American about this industry. It is the very essence of a global enterprise. Roughly half of the largest drug companies are based in Europe. (The exact count shifts because of mergers.) In 2002, the top ten were the American companies Pfizer, Merck, Johnson & Johnson, Bristol-Myers Squibb, and Wyeth (formerly American Home Products); the British companies GlaxoSmithKline and AstraZeneca; the Swiss companies Novartis and Roche; and the French company Aventis (which in 2004 merged with another French company, Sanafi Synthelabo, putting it in third place).[5] All are much alike in their operations. All price their drugs much higher here than in other markets.

Since the United States is the major profit center, it is simply good public relations for drug companies to pass themselves off as American, whether they are or not. It is true, however, that some of the European companies are now locating their R&D operations in the United States. They claim the reason for this is that we don't regulate prices, as does much of the rest of the world. But more likely it is that they want to feed on the unparalleled research output of American universities and the NIH. In other words, it's not private enterprise that draws them here but the very opposite—our publicly sponsored research enterprise.

ver the past two decades the pharmaceutical industry has moved very far from its original high purpose of discovering and producing useful new drugs. Now primarily a marketing machine to sell drugs of dubious benefit, this industry uses its wealth and power to co-opt every institution that might stand in its way, including the US Congress, the FDA, academic medical centers, and the medical profession itself. (Most of its marketing efforts are focused on influencing doctors, since they must write the prescriptions.)

If prescription drugs were like ordinary consumer goods, all this might not matter very much. But drugs are different. People depend on them for their health and even their lives. In the words of Senator Debbie Stabenow (D-Mich.), "It's not like buying a car or tennis shoes or peanut butter." People need to know that there are some checks and balances on this industry, so that its quest for profits doesn't push every other consideration aside. But there aren't such checks and balances.

2.

What does the eight-hundred-pound gorilla do? Anything it wants to.
What's true of the eight-hundred-pound gorilla is true of the colossus that is the pharmaceutical industry. It is used to doing pretty much what it wants to do. The watershed year was 1980. Before then, it was a good business, but afterward, it was a stupendous one. From 1960 to 1980, prescription drug sales were fairly static as a percent of US gross domestic product, but from 1980 to 2000, they tripled. They now stand at more than $200 billion a year.[6] Of the many events that contributed to the industry's great and good fortune, none had to do with the quality of the drugs the companies were selling.

The claim that drugs are a $200 billion industry is an understatement. According to government sources, that is roughly how much Americans spent on prescription drugs in 2002. That figure refers to direct consumer purchases at drugstores and mail-order pharmacies (whether paid for out of pocket or not), and it includes the nearly 25 percent markup for wholesalers, pharmacists, and other middlemen and retailers. But it does not include the large amounts spent for drugs administered in hospitals, nursing homes, or doctors' offices (as is the case for many cancer drugs). In most analyses, they are allocated to costs for those facilities.

Drug company revenues (or sales) are a little different, at least as they are reported in summaries of corporate annual reports. They usually refer to a company's worldwide sales, including those to health facilities. But they do not include the revenues of middlemen and retailers.

Perhaps the most quoted source of statistics on the pharmaceutical industry, IMS Health, estimated total worldwide sales for prescription drugs to be about $400 billion in 2002. About half were in the United States. So the $200 billion colossus is really a $400 billion megacolossus.

he election of Ronald Reagan in 1980 was perhaps the fundamental element in the rapid rise of big pharma—the collective name for the largest drug companies. With the Reagan administration came a strong pro-business shift not only in government policies but in society at large. And with the shift, the public attitude toward great wealth changed. Before then, there was something faintly disreputable about really big fortunes. You could choose to do well or you could choose to do good, but most people who had any choice in the matter thought it difficult to do both. That belief was particularly strong among scientists and other intellectuals. They could choose to live a comfortable but not luxurious life in academia, hoping to do exciting cutting-edge research, or they could "sell out" to industry and do less important but more remunerative work. Starting in the Reagan years and continuing through the 1990s, Americans changed their tune. It became not only reputable to be wealthy, but something close to virtuous. There were "winners" and there were "losers," and the winners were rich and deserved to be. The gap between the rich and poor, which had been narrowing since World War II, suddenly began to widen again, until today it is a chasm.

The pharmaceutical industry and its CEOs quickly joined the ranks of the winners as a result of a number of business-friendly government actions. I won't enumerate all of them, but two are especially important. Beginning in 1980, Congress enacted a series of laws designed to speed the translation of tax-supported basic research into useful new products—a process sometimes referred to as "technology transfer." The goal was also to improve the position of American-owned high-tech businesses in world markets.

The most important of these laws is known as the Bayh-Dole Act, after its chief sponsors, Senator Birch Bayh (D-Ind.) and Senator Robert Dole (R-Kans.). Bayh-Dole enabled universities and small businesses to patent discoveries emanating from research sponsored by the National Institutes of Health, the major distributor of tax dollars for medical research, and then to grant exclusive licenses to drug companies. Until then, taxpayer-financed discoveries were in the public domain, available to any company that wanted to use them. But now universities, where most NIH-sponsored work is carried out, can patent and license their discoveries, and charge royalties. Similar legislation permitted the NIH itself to enter into deals with drug companies that would directly transfer NIH discoveries to industry.

Bayh-Dole gave a tremendous boost to the nascent biotechnology industry, as well as to big pharma. Small biotech companies, many of them founded by university researchers to exploit their discoveries, proliferated rapidly. They now ring the major academic research institutions and often carry out the initial phases of drug development, hoping for lucrative deals with big drug companies that can market the new drugs. Usually both academic researchers and their institutions own equity in the biotechnology companies they are involved with. Thus, when a patent held by a university or a small biotech company is eventually licensed to a big drug company, all parties cash in on the public investment in research.

hese laws mean that drug companies no longer have to rely on their own research for new drugs, and few of the large ones do. Increasingly, they rely on academia, small biotech startup companies, and the NIH for that.[7] At least a third of drugs marketed by the major drug companies are now licensed from universities or small biotech companies, and these tend to be the most innovative ones.[8] While Bayh-Dole was clearly a bonanza for big pharma and the biotech industry, whether its enactment was a net benefit to the public is arguable.

The Reagan years and Bayh-Dole also transformed the ethos of medical schools and teaching hospitals. These nonprofit institutions started to see themselves as "partners" of industry, and they became just as enthusiastic as any entrepreneur about the opportunities to parlay their discoveries into financial gain. Faculty researchers were encouraged to obtain patents on their work (which were assigned to their universities), and they shared in the royalties. Many medical schools and teaching hospitals set up "technology transfer" offices to help in this activity and capitalize on faculty discoveries. As the entrepreneurial spirit grew during the 1990s, medical school faculty entered into other lucrative financial arrangements with drug companies, as did their parent institutions.

One of the results has been a growing pro-industry bias in medical research—exactly where such bias doesn't belong. Faculty members who had earlier contented themselves with what was once referred to as a "threadbare but genteel" lifestyle began to ask themselves, in the words of my grandmother, "If you're so smart, why aren't you rich?" Medical schools and teaching hospitals, for their part, put more resources into searching for commercial opportunities.

Starting in 1984, with legislation known as the Hatch-Waxman Act, Congress passed another series of laws that were just as big a bonanza for the pharmaceutical industry. These laws extended monopoly rights for brand-name drugs. Exclusivity is the lifeblood of the industry because it means that no other company may sell the same drug for a set period. After exclusive marketing rights expire, copies (called generic drugs) enter the market, and the price usually falls to as little as 20 percent of what it was.[9] There are two forms of monopoly rights—patents granted by the US Patent and Trade Office (USPTO) and exclusivity granted by the FDA. While related, they operate somewhat independently, almost as backups for each other. Hatch-Waxman, named for Senator Orrin Hatch (R-Utah) and Representative Henry Waxman (D-Calif.), was meant mainly to stimulate the foundering generic industry by short-circuiting some of the FDA requirements for bringing generic drugs to market. While successful in doing that, Hatch-Waxman also lengthened the patent life for brand-name drugs. Since then, industry lawyers have manipulated some of its provisions to extend patents far longer than the lawmakers intended.

In the 1990s, Congress enacted other laws that further increased the patent life of brand-name drugs. Drug companies now employ small armies of lawyers to milk these laws for all they're worth—and they're worth a lot. The result is that the effective patent life of brand-name drugs increased from about eight years in 1980 to about fourteen years in 2000.[10] For a blockbuster—usually defined as a drug with sales of over a billion dollars a year (like Lipitor or Celebrex or Zoloft)—those six years of additional exclusivity are golden. They can add billions of dollars to sales—enough to buy a lot of lawyers and have plenty of change left over. No wonder big pharma will do almost anything to protect exclusive marketing rights, despite the fact that doing so flies in the face of all its rhetoric about the free market.

s their profits skyrocketed during the 1980s and 1990s, so did the political power of drug companies. By 1990, the industry had assumed its present contours as a business with unprecedented control over its own fortunes. For example, if it didn't like something about the FDA, the federal agency that is supposed to regulate the industry, it could change it through direct pressure or through its friends in Congress. The top ten drug companies (which included European companies) had profits of nearly 25 percent of sales in 1990, and except for a dip at the time of President Bill Clinton's health care reform proposal, profits as a percentage of sales remained about the same for the next decade. (Of course, in absolute terms, as sales mounted, so did profits.) In 2001, the ten American drug companies in the Fortune 500 list (not quite the same as the top ten worldwide, but their profit margins are much the same) ranked far above all other American industries in average net return, whether as a percentage of sales (18.5 percent), of assets (16.3 percent), or of shareholders' equity (33.2 percent). These are astonishing margins. For comparison, the median net return for all other industries in the Fortune 500 was only 3.3 percent of sales. Commercial banking, itself no slouch as an aggressive industry with many friends in high places, was a distant second, at 13.5 percent of sales.[11]

In 2002, as the economic downturn continued, big pharma showed only a slight drop in profits—from 18.5 to 17.0 percent of sales. The most startling fact about 2002 is that the combined profits for the ten drug companies in the Fortune 500 ($35.9 billion) were more than the profits for all the other 490 businesses put together ($33.7 billion).[12] In 2003 profits of the Fortune 500 drug companies dropped to 14.3 percent of sales, still well above the median for all industries of 4.6 percent for that year. When I say this is a profitable industry, I mean really profitable. It is difficult to conceive of how awash in money big pharma is.

Drug industry expenditures for research and development, while large, were consistently far less than profits. For the top ten companies, they amounted to only 11 percent of sales in 1990, rising slightly to 14 percent in 2000. The biggest single item in the budget is neither R&D nor even profits but something usually called "marketing and administration"—a name that varies slightly from company to company. In 1990, a staggering 36 percent of sales revenues went into this category, and that proportion remained about the same for over a decade.[13] Note that this is two and a half times the expenditures for R&D.

These figures are drawn from the industry's own annual reports to the Securities and Exchange Commission (SEC) and to stockholders, but what actually goes into these categories is not at all clear, because drug companies hold that information very close to their chests. It is likely, for instance, that R&D includes many activities most people would consider marketing, but no one can know for sure. For its part, "marketing and administration" is a gigantic black box that probably includes what the industry calls "education," as well as advertising and promotion, legal costs, and executive salaries—which are whopping. According to a report by the non-profit group Families USA, the for-mer chairman and CEO of Bristol-Myers Squibb, Charles A. Heimbold Jr., made $74,890,918 in 2001, not counting his $76,095,611 worth of unexercised stock options. The chairman of Wyeth made $40,521,011, exclusive of his $40,629,459 in stock options. And so on.[14]

3.

If 1980 was a watershed year for the pharmaceutical industry, 2000 may very well turn out to have been another one—the year things began to go wrong. As the booming economy of the late 1990s turned sour, many successful businesses found themselves in trouble. And as tax revenues dropped, state governments also found themselves in trouble. In one respect, the pharmaceutical industry is well protected against the downturn, since it has so much wealth and power. But in another respect, it is peculiarly vulnerable, since it depends on employer-sponsored insurance and state-run Medicaid programs for much of its revenues. When employers and states are in trouble, so is big pharma.

And sure enough, in just the past couple of years, employers and the private health insurers with whom they contract have started to push back against drug costs. Most big managed care plans now bargain for steep price discounts. Most have also instituted three-tiered coverage for prescription drugs—full coverage for generic drugs, partial coverage for useful brand-name drugs, and no coverage for expensive drugs that offer no added benefit over cheaper ones. These lists of preferred drugs are called formularies, and they are an increasingly important method for containing drug costs. Big pharma is feeling the effects of these measures, although not surprisingly, it has become adept at manipulating the system—mainly by inducing doctors or health plans to put expensive, brand-name drugs on formularies.

State governments, too, are looking for ways to cut their drug costs. Some state legislatures are drafting measures that would permit them to regulate prescription drug prices for state employees, Medicaid recipients, and the uninsured. Like managed care plans, they are creating formularies of preferred drugs. The industry is fighting these efforts—mainly with its legions of lobbyists and lawyers. It fought the state of Maine all the way to the US Supreme Court, which in 2003 upheld Maine's right to bargain with drug companies for lower prices, while leaving open the details. But that war has just begun, and it promises to go on for years and get very ugly.

Recently the public has shown signs of being fed up. The fact that Americans pay much more for prescription drugs than Europeans and Canadians is now widely known. An estimated one to two million Americans buy their medicines from Canadian drugstores over the Internet, despite the fact that in 1987, in response to heavy industry lobbying, a compliant Congress had made it illegal for anyone other than manufacturers to import prescription drugs from other countries.[15] In addition, there is a brisk traffic in bus trips for people in border states, particularly the elderly, to travel to Canada or Mexico to buy prescription drugs. Their resentment is palpable, and they constitute a powerful voter block—a fact not lost on Congress or state legislatures.

The industry faces other, less familiar problems. It happens that, by chance, some of the top-selling drugs—with combined sales of around $35 billion a year—are scheduled to go off patent within a few years of one another.[16] This drop over the cliff began in 2001, with the expiration of Eli Lilly's patent on its blockbuster antidepressant Prozac. In the same year, AstraZeneca lost its patent on Prilosec, the original "purple pill" for heartburn, which at its peak brought in a stunning $6 billion a year. Bristol-Myers Squibb lost its best-selling diabetes drug, Glucophage. The unusual cluster of expirations will continue for another couple of years. While it represents a huge loss to the industry as a whole, for some companies it's a disaster. Schering-Plough's blockbuster allergy drug, Claritin, brought in fully a third of that company's revenues before its patent expired in 2002.[17] Claritin is now sold over the counter for much less than its prescription price. So far, the company has been unable to make up for the loss by trying to switch Claritin users to Clarinex—a drug that is virtually identical but has the advantage of still being on patent.

Even worse is the fact that there are very few drugs in the pipeline ready to take the place of blockbusters going off patent. In fact, that is the biggest problem facing the industry today, and its darkest secret. All the public relations about innovation is meant to obscure precisely this fact. The stream of new drugs has slowed to a trickle, and few of them are innovative in any sense of that word. Instead, the great majority are variations of oldies but goodies—"me-too" drugs.

Of the seventy-eight drugs approved by the FDA in 2002, only seventeen contained new active ingredients, and only seven of these were classified by the FDA as improvements over older drugs. The other seventy-one drugs approved that year were variations of old drugs or deemed no better than drugs already on the market. In other words, they were me-too drugs. Seven of seventy-eight is not much of a yield. Furthermore, of those seven, not one came from a major US drug company.[18]

or the first time, in just a few short years, the gigantic pharmaceutical industry is finding itself in serious difficulty. It is facing, as one industry spokesman put it, "a perfect storm." To be sure, profits are still beyond anything most other industries could hope for, but they have recently fallen, and for some companies they fell a lot. And that is what matters to investors. Wall Street doesn't care how high profits are today, only how high they will be tomorrow. For some companies, stock prices have plummeted. Nevertheless, the industry keeps promising a bright new day. It bases its reassurances on the notion that the mapping of the human genome and the accompanying burst in genetic research will yield a cornucopia of important new drugs. Left unsaid is the fact that big pharma is depending on government, universities, and small biotech companies for that innovation. While there is no doubt that genetic discoveries will lead to treatments, the fact remains that it will probably be years before the basic research pays off with new drugs. In the meantime, the once-solid foundations of the big pharma colossus are shaking.

The hints of trouble and the public's growing resentment over high prices are producing the first cracks in the industry's formerly firm support in Washington. In 2000, Congress passed legislation that would have closed some of the loopholes in Hatch-Waxman and also permitted American pharmacies, as well as individuals, to import drugs from certain countries where prices are lower. In particular, they could buy back FDA-approved drugs from Canada that had been exported there. It sounds silly to "reimport" drugs that are marketed in the United States, but even with the added transaction costs, doing so is cheaper than buying them here. But the bill required the secretary of health and human services to certify that the practice would not pose any "added risk" to the public, and secretaries in both the Clinton and Bush administrations, under pressure from the industry, refused to do that.

The industry is also being hit with a tidal wave of government investigations and civil and criminal lawsuits. The litany of charges includes illegally overcharging Medicaid and Medicare, paying kickbacks to doctors, engaging in anticompetitive practices, colluding with generic companies to keep generic drugs off the market, illegally promoting drugs for unapproved uses, engaging in misleading direct-to-consumer advertising, and, of course, covering up evidence. Some of the settlements have been huge. TAP Pharmaceuticals, for instance, paid $875 million to settle civil and criminal charges of Medicaid and Medicare fraud in the marketing of its prostate cancer drug, Lupron.[19] All of these efforts could be summed up as increasingly desperate marketing and patent games, activities that always skirted the edge of legality but now are sometimes well on the other side.

How is the pharmaceutical industry responding to its difficulties? One could hope drug companies would decide to make some changes—trim their prices, or at least make them more equitable, and put more of their money into trying to discover genuinely innovative drugs, instead of just talking about it. But that is not what is happening. Instead, drug companies are doing more of what got them into this situation. They are marketing their me-too drugs even more relentlessly. They are pushing even harder to extend their monopolies on top-selling drugs. And they are pouring more money into lobbying and political campaigns. As for innovation, they are still waiting for Godot.

The news is not all bad for the industry. The Medicare prescription drug benefit enacted in 2003, and scheduled to go into effect in 2006, promises a windfall for big pharma since it forbids the government from negotiating prices. The immediate jump in pharmaceutical stock prices after the bill passed indicated that the industry and investors were well aware of the windfall. But at best, this legislation will be only a temporary boost for the industry. As costs rise, Congress will have to reconsider its industry-friendly decision to allow drug companies to set their own prices, no questions asked.

his is an industry that in some ways is like the Wizard of Oz—still full of bluster but now being exposed as something far different from its image. Instead of being an engine of innovation, it is a vast marketing machine. Instead of being a free market success story, it lives off government-funded research and monopoly rights. Yet this industry occupies an essential role in the American health care system, and it performs a valuable function, if not in discovering important new drugs at least in developing them and bringing them to market. But big pharma is extravagantly rewarded for its relatively modest functions. We get nowhere near our money's worth. The United States can no longer afford it in its present form.

Clearly, the pharmaceutical industry is due for fundamental reform. Reform will have to extend beyond the industry to the agencies and institutions it has co-opted, including the FDA and the medical profession and its teaching centers. In my forthcoming book, The Truth About the Drug Companies, I discuss the major reforms that will be necessary.

For example, we need to get the industry to focus on discovering truly innovative drugs instead of turning out me-too drugs (and spending billions of dollars to promote them as though they were miracles). The me-too business is made possible by the fact that the FDA usually approves a drug only if it is better than a placebo. It needn't be better than an older drug already on the market to treat the same condition; in fact, it may be worse. There is no way of knowing, since companies generally do not test their new drugs against older ones for the same conditions at equivalent doses. (For obvious reasons, they would rather not find the answer.) They should be required to do so.

The me-too market would collapse virtually overnight if the FDA made approval of new drugs contingent on their being better in some important way than older drugs already on the market. Probably very few new drugs could meet that test. By default, then, drug companies would have to concentrate on finding truly innovative drugs, and we would finally find out whether this much-vaunted industry is turning out better drugs. A welcome by-product of this reform is that it would also reduce the incessant and enormously expensive marketing necessary to jockey for position in the me-too market. Genuinely important new drugs do not need much promotion (imagine having to advertise a cure for cancer).

A second important reform would be to require drug companies to open their books. Drug companies reveal very little about the most crucial aspects of their business. We know next to nothing about how much they spend to bring each drug to market or what they spend it on. (We know that it is not $802 million, as some industry apologists have recently claimed.) Nor do we know what their gigantic "marketing and administration" budgets cover. We don't even know the prices they charge their various customers. Perhaps most important, we do not know the results of the clinical trials they sponsor—only those they choose to make public, which tend to be the most favorable findings. (The FDA is not allowed to reveal the results it has.) The industry claims all of this is "proprietary" information. Yet, unlike other businesses, drug companies are dependent on the public for a host of special favors—including the rights to NIH-funded research, long periods of market monopoly, and multiple tax breaks that almost guarantee a profit. Because of these special favors and the importance of its products to public health, as well as the fact that the government is a major purchaser of its products, the pharmaceutical industry should be regarded much as a public utility.

These are just two of many reforms I advocate in my book. Some of the others have to do with breaking the dependence of the medical profession on the industry and with the inappropriate control drug companies have over the evaluation of their own products. The sort of thoroughgoing changes required will take government action, which in turn will require strong public pressure. It will be tough. Drug companies have the largest lobby in Washington, and they give copiously to political campaigns. Legislators are now so beholden to the pharmaceutical industry that it will be exceedingly difficult to break its lock on them.

But the one thing legislators need more than campaign contributions is votes. That is why citizens should know what is really going on. Contrary to the industry's public relations, they don't get what they pay for. The fact is that this industry is taking us for a ride, and there will be no real reform without an aroused and determined public to make it happen.

Notes
[1] There are several sources of statistics on the size and growth of the industry. One is IMS Health (www.imshealth .com), a private company that collects and sells information on the global pharmaceutical industry. See www .imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_41336931,00. html for the $200 billion figure. For further sources on this and other matters, see my book The Truth About the Drug Companies: How They Deceive Us and What to Do About It (to be published in August by Random House), from which this article is drawn.

[2] For a full picture of the special burden of rising drug prices on senior citizens, see Families USA, "Out-of-Bounds: Rising Prescription Drug Prices for Seniors" (www.familiesusa .org/site/PageServer?pagename=Publications_Reports).

[3] Sarah Lueck, "Drug Prices Far Outpace Inflation," The Wall Street Journal, July 10, 2003, p. D2.

[4] On ABC Special with Peter Jennings, "Bitter Medicine: Pills, Profit, and the Public Health," May 29, 2002.

[5] For the top ten companies and their recent mergers as of 2003, see www .oligopolywatch.com/2003/05/25.html.

[6] These figures come from the US Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group, Baltimore, Maryland. They were summarized in Cynthia Smith, "Retail Prescription Drug Spending in the National Health Accounts," Health Affairs, January– February 2004, p. 160.

[7] For excellent summaries of public contributions to drug company research, see Public Citizen Congress Watch, "Rx R&D Myths: The Case Against the Drug Industry's R&D 'Scare Card,'" July 2001 (www.citizen.org); and NIHCM, "Changing Patterns of Pharmaceutical Innovation," May 2002 (www.nihcm.org).

[8] This is probably an underestimate. One source that indicates it is at least this is CenterWatch, www.centerwatch .com, a private company owned by Thomson Medical Economics, which provides information to the clinical trial industry. See An Industry in Evolution, third edition, edited by Mary Jo Lamberti (CenterWatch, 2001), p. 22.

[9] Families USA, "Out-of-Bounds: Rising Prescription Drug Prices for Seniors."

[10] Public Citizen Congress Watch, "Rx R&D Myths."

[11] "The Fortune 500," Fortune, April 15, 2002, p. F26.

[12] Public Citizen Congress Watch, "Drug Industry Profits: Hefty Pharmaceutical Company Margins Dwarf Other Industries," June 2003 (www.citizen .org/documents/Pharma_Report.pdf). The data are drawn mainly from the Fortune 500 list in Fortune, April 7, 2003, and drug company annual reports.

[13] Henry J. Kaiser Family Foundation, "Prescription Drug Trends," November 2001 (www.kff.org).

[14] FamiliesUSA, "Profiting from Pain: Where Prescription Drug Dollars Go," July 2002 (www.familiesusa. org /site/DocServer/PReport.pdf?docID= 249).

[15] Patricia Barry, "More Americans Go North for Drugs," AARP Bulletin, April 2003, p. 3.

[16] Chandrani Ghosh and Andrew Tanzer, "Patent Play," Forbes, September 17, 2001, p. 141.

[17] Gardiner Harris, "Schering-Plough Is Hurt by Plummeting Pill Costs," The New York Times, July 8, 2003, p. C1.

[18] For key information about the numbers and kinds of drugs approved each year, see the Web site of the US Food and Drug Administration (FDA), www .fda.gov/cder/rdmt/pstable.htm.

[19] Alice Dembner, "Drug Firm to Pay $875M Fine for Fraud," The Boston Globe, October 4, 2001, p. A13.

Letters
December 16, 2004: Lawrence Sincich, The Drug Companies and the Universities

Friday, February 20, 2004

The Primary Beneficiaries of the Bush Tax Cuts are the Wealthy

FactCheck.org straightens out some of the distortions in discussions about the beneficiaries of the 2003 Bush tax cuts:

Here We Go Again: Bush Exaggerates Tax Cuts
February 20, 2004
The President can't keep his figures straight. And most people are getting less than he implies.

Summary
President Bush stumbled Feb. 19, saying the average tax cut is $1,089. The White House corrected that figure to $1,586. But the fact is that most Americans won't see anywhere near either of those amounts.
As we've said before when disputing equally misleading lowball figures given by Howard Dean, half of all individuals and families will get less than $470, and half will get more. The “average” is misleading because it is inflated by very large cuts given to a relative few at the top.

Analysis
Now that the general election campaign is nearing, President Bush has resumed a sales pitch for the tax cuts he's signed. But he persists in making some misleading claims.

At a 24-minute appearance in the White House complex on Feb. 19, the President wrongly stated that "everybody who pays taxes" is getting a cut, which is not true:

Bush: We cut the taxes on everybody who pays taxes. I don't think it makes sense for tax-cutters to say, okay, you win, and you lose. My attitude was, if you pay taxes, you ought to get relief. And we cut all taxes,

In fact, all taxes were not cut and millions who pay only federal payroll taxes got no benefit from Bush's cuts.

It is true that everybody who paid federal income taxes is getting a cut. But according to the nonpartisan Tax Policy Center, 35.6 million individuals and families got zero benefit from the Bush cuts because their income was so low they were not paying federal income taxes before the cuts. This number includes 15.1 million workers who are paying federal payroll taxes for Social Security and Medicare. That's 15 million "taxpayers" who were left out.

The President also bobbled the numbers when describing the average size of the cut. Here's the official White House transcript of what he said, which was wrong, along with the footnotes inserted later by the White House staff to correct the record:

Bush: The tax relief we passed, 11 million* taxpayers this year will save $1,086* off their taxes. . . .

(* 111 million taxpayers will save, on average, $1,586 off their taxes.)

The $1,586 figure is indeed an accurate statement of the average cut received by those who are getting a cut, according to the Treasury Department. However, it is far from typical.

For one thing, the figure does not take into account the 25% of all individuals and families who are receiving zero tax cut this year. It is an average only of those who are getting some cut. When those who get nothing are added in the average cut drops to $1,217, according to the Tax Policy Center.

But most importantly, the average is inflated by the fact that most of the money is going to a relatively few taxpayers at the top of the income scale, as seen from the following table distilled from a more extensive analysis by the Tax Policy Center:

Combined Effect of Bush Tax Cuts 2003

Income
(in thousands) Percent of Households Average Tax Change
Less than 10 23.7 -$8
10-20 16.6 -$307
20-30 13.3 -$638
30-40 9.7 -$825
40-50 7.6 -$1,012
50-75 13.0 -$1,403
75-100 6.8 -$2,543
100-200 6.6 -$3,710
200-500 1.6 -$7,173
500-1,000 0.3 -$22,485
More than 1,000 0.1 -$112,925
Source: Tax Policy Center table T03-0123
Taxpayers making more than $1 million a year get an average cut of nearly $113,000 this year. Such huge cuts at the top tend to pull up the numerical average that the President is fond of citing.

A more meaningful number is the median -- or mid-point. The Tax Policy Center calculates the median cut received for income earned in 2003 is $470.

That means half of all individuals and families get less than that, and half get more.

Even the median figure doesn't give a full picture of how the benefits are spread around, however. Taxpayers make out very differently depending on whether they are married or single, and how many children they have under age 17.

That's because much of the tax relief for 2003 comes in the form of a tax break for married couples -- reduction of the so-called "marriage penalty" -- and a doubling of the tax credit granted for each child under 17, to $1,000 per child. Those do nothing to benefit single taxpayers -- including unmarried workers and millions of elderly widows and widowers, for example. In fact, the Tax Policy Center calculates that nearly 13 million of those over age 65 will get no tax cut.

On the other hand, the Bush cuts do reduce income taxes for many middle-income families to zero this year -- taking them off the federal income tax rolls entirely.

The following table, also from the Tax Policy Center, shows how different types of families in various income ranges make out under the Bush cuts this year:

Combined Effect of Bush Cuts for 2003: Typical Families

(Amounts by which federal income taxes would rise if cuts are repealed)

Income

Single

Married Filing Joint

# of kids under 17–>

0

0

1

2

3

$10,000

$110

$76

$0

$0

$0

$15,000

350

142

610

661

661

$25,000

350

702

1,210

1,661

1,579

$35,000

350

932

1,433

1,897

2,245

$50,000

669

773

1,272

1,773

2,271

$75,000

1,318

1,714

1,817

1,938

2,437

$100,000

2,001

2,596

3,004

3,413

4,510

$125,000

2,695

3,277

3,435

4,094

4,571

$150,000

3,460

4,010

3,918

3,827

4,735

$200,000

5,218

5,623

5,531

4,918

4,364

$500,000

15,585

12,328

12,328

12,328

12,328

$1,000,000

37,713

38,426

38,426

38,426

38,426

Source: Tax Policy Center Table T03-0200

The President is not the only politician who distorts the figures regarding the tax cuts, of course. As we've pointed out before, Howard Dean persisted in a false claim that "sixty percent of us got only $304," when in fact most taxpayers got more.

And some of the points in the President's election-year sales pitch are perfectly valid. For example:

Bush: Nearly 5 million taxpayers will be off the rolls as a result of the tax relief this year.

That's true for federal income taxes -- close to 5 million who previously owed some federal income tax will owe none under the Bush cuts, including many middle-income families with children.

We'll no doubt be hearing more about the tax cuts in the months to come. Both Kerry and Edwards, currently slugging it out for the Democratic nomination, have called for repeal of portions of the Bush cuts that benefit upper-income taxpayers.

Sources
George W. Bush " Remarks by the President on the Economy" Presidential Hall, Eisenhower Executive Office Building 19 Feb. 2004.
Elisabeth Bumiller, “Bush Promotes His Tax Cuts as Beneficiaries Stand By” New York Times 20 Feb. 2004.

Table T03-0123 "Combined Effect of EGTRRA and Conference Agreement on the Jobs and Growth Tax Relief Reconciliation Act of 2003: Distribution of Income Tax Change by AGI Class, 2003" Tax Policy Center Washington DC 23 May 2003.

Table T03-0163 "Combined Effect of EGTRRA and JGTRRA: Number of Tax Units by Size of Income Tax Cut and Individual Characteristics, 2003" Tax Policy Center Washington DC 23 June 2003.

Table T03-0200 "The 2001 and 2003 Tax Cuts for Representative Families By Type of Filer for Tax Year 2003" Tax Policy Center Washington DC 2 Jan 2004.

Monday, January 20, 2003

The lucky duckies who pay no income taxes - another look

According to the January 20, 2003 Wall Street Journal editorial "Lucky Duckies Again: Look at who won't pay taxes under Bush's plan":
As you may have noticed, the critics of President Bush's new tax cut package claim it is a sop to the rich. This charge makes us wonder if they've even read the plan. The truth is that the Bush proposals would make the tax code more progressive, not less. And this isn't altogether a good thing.

The soak-the-rich facts, if any journalists cared to look, are contained in the income distribution tables on the plan compiled by the Treasury Department. Looking at the impact for 2003, Treasury finds that the average reduction in income taxes is a touch more than 12%. But for those who make less than $30,000 the average reduction is about 17%, while for those who earn more than $100,000 it is 11.4% or less. (See the table below.)

There's even better news for modern Robin Hoods. Because the percentage reduction for families with incomes under $50,000 is greater under the Bush plan, those families would pay a smaller share of the total income tax than they do under current law.

Tax Cuts for the Poor
Lower earners would get a larger percentage income tax cut on average under the Bush plan.
Income
Percentage reduction
0-$30,000
17.0%
30-40,000
20.1%
40-50,000
14.5%
50-75,000
11.4%
75-100,000
13%
100-200,000
11.4%
200,000-plus
11.2%
Total
12.3%
Families with incomes over $100,000 would end up paying a larger share of the total income tax. These families would pay 73% of all federal income taxes. Not to put too fine a point on this income redistribution, but taxpayers with incomes over $200,000 could expect on average to pay about $99,000 in taxes under Mr. Bush's plan.


How could this happen? Mr. Bush would relieve 3.8 million lower-income taxpayers from paying any income taxes. The chief tax remover comes from his proposal to accelerate the increase in the child credit to $1,000 from $600, bumping a touch more than three million taxpayers right off the rolls.

No doubt the Bush team proposed this tilt toward lower income taxpayers to mute the class-warrior critics, not that we've noticed any lower decibel level. But one certain consequence is that the plan exacerbates the growing problem of a bifurcated tax system.

We raised this issue several weeks ago, pointing out that the unceasing addition of exemptions, deductions and credits to the tax code was shrinking the tax-paying base. And, as more lower-income people saw tax liabilities fall to zero, more upper-income people shouldered a larger part of the tax burden. We did not, by the way, suggest that lower income people should pay higher taxes. We even went out of our way to flog our favorite horse that everybody should pay less in taxes.

We are merely pointing out the (apparently heretical) truth that the current tax system is very skewed against upper-income Americans. According to IRS data from 2000, the top 5% of tax filers paid more than 50% of total income tax revenue, and the top half of tax filers were responsible for almost all revenue--96% of the total take. This burden on the upper-income holds even when the payroll tax is included in overall distribution tables. (The payroll tax includes the regressive Social Security levy and the 1.45% Medicare tax that applies to every dollar of income.)

The Congressional Budget Office has looked at the distributive impact of various taxes for 1997. The income-tax share of the lowest-income family quintile (the bottom 20%) was negative 1.2% and the share of the highest family quintile was 73.3%. The difference in payroll-tax share was somewhat less dramatic at 3.9% for the lowest quintile and 40.6% for the highest. But when all federal taxes were thrown together, the share of the lowest quintile was 1.6%, while the share of the highest quintile was 60.2%. Karl Marx, call your office.



This super-progressivity comes from two sources: the system of higher marginal-rate brackets for higher income households, and the exclusion of lower income households from any income-tax liability. In 2000, of 129.4 million tax returns filed, about 32 million paid no taxes. Most of these lucky duckies, as we have called them (to some amusing consternation), benefit from tax exemptions, deductions and credits that violate the concept of horizontal tax equity--the notion that people with identical incomes should pay the same amount in taxes.

For instance, the folks at the Tax Foundation have looked at how two single moms--each earning $30,000 a year--would fare under the Bush plan. In 2003, the single mom with one child would pay income tax of $1,028; the mom with two children would not only pay no taxes, she'd also receive a check from the federal government, under the earned income tax credit, for $680. Compared to the single mom who must pay taxes, the single mom who does not is, well, a lucky ducky.

The broader point is that whatever Mr. Bush's tax proposal does for economic growth (and we think it'd do a lot), it gives more proportional benefit to lower-income households. The class warriors should be thrilled.


Also see the editorial "The Non-Taxpaying Class: Those lucky duckies!" which originally appeared in The Wall Street Journal on November 20, 2002.

Sunday, January 12, 2003

Explaining Why People Oppose Policies That Would Benefit Them

In the January 12, 2003 New York Times editorial "The Triumph Of Hope Over Self-Interest," David Brooks explains why people vote against some policies that would benefit them:
Why don't people vote their own self-interest? Every few years the Republicans propose a tax cut, and every few years the Democrats pull out their income distribution charts to show that much of the benefits of the Republican plan go to the richest 1 percent of Americans or thereabouts. And yet every few years a Republican plan wends its way through the legislative process and, with some trims and amendments, passes.

The Democrats couldn't even persuade people to oppose the repeal of the estate tax, which is explicitly for the mega-upper class. Al Gore, who ran a populist campaign, couldn't even win the votes of white males who didn't go to college, whose incomes have stagnated over the past decades and who were the explicit targets of his campaign. Why don't more Americans want to distribute more wealth down to people like themselves?

Well, as the academics would say, it's overdetermined. There are several reasons.

People vote their aspirations.

The most telling polling result from the 2000 election was from a Time magazine survey that asked people if they are in the top 1 percent of earners. Nineteen percent of Americans say they are in the richest 1 percent and a further 20 percent expect to be someday. So right away you have 39 percent of Americans who thought that when Mr. Gore savaged a plan that favored the top 1 percent, he was taking a direct shot at them.

It's not hard to see why they think this way. Americans live in a culture of abundance. They have always had a sense that great opportunities lie just over the horizon, in the next valley, with the next job or the next big thing. None of us is really poor; we're just pre-rich.

Americans read magazines for people more affluent than they are (W, Cigar Aficionado, The New Yorker, Robb Report, Town and Country) because they think that someday they could be that guy with the tastefully appointed horse farm. Democratic politicians proposing to take from the rich are just bashing the dreams of our imminent selves.

Income resentment is not a strong emotion in much of America.

If you earn $125,000 a year and live in Manhattan, certainly, you are surrounded by things you cannot afford. You have to walk by those buildings on Central Park West with the 2,500-square-foot apartments that are empty three-quarters of the year because their evil owners are mostly living at their other houses in L.A.

But if you are a middle-class person in most of America, you are not brought into incessant contact with things you can't afford. There aren't Lexus dealerships on every corner. There are no snooty restaurants with water sommeliers to help you sort though the bottled eau selections. You can afford most of the things at Wal-Mart or Kohl's and the occasional meal at the Macaroni Grill. Moreover, it would be socially unacceptable for you to pull up to church in a Jaguar or to hire a caterer for your dinner party anyway. So you are not plagued by a nagging feeling of doing without.

Many Americans admire the rich.

They don't see society as a conflict zone between the rich and poor. It's taboo to say in a democratic culture, but do you think a nation that watches Katie Couric in the morning, Tom Hanks in the evening and Michael Jordan on weekends harbors deep animosity toward the affluent?

On the contrary. I'm writing this from Nashville, where one of the richest families, the Frists, is hugely admired for its entrepreneurial skill and community service. People don't want to tax the Frists -- they want to elect them to the Senate. And they did.

Nor are Americans suffering from false consciousness. You go to a town where the factories have closed and people who once earned $14 an hour now work for $8 an hour. They've taken their hits. But odds are you will find their faith in hard work and self-reliance undiminished, and their suspicion of Washington unchanged.

Americans resent social inequality more than income inequality.

As the sociologist Jennifer Lopez has observed: ''Don't be fooled by the rocks that I got, I'm just, I'm just Jenny from the block.'' As long as rich people ''stay real,'' in Ms. Lopez's formulation, they are admired. Meanwhile, middle-class journalists and academics who seem to look down on megachurches, suburbia and hunters are resented. If Americans see the tax debate as being waged between the economic elite, led by President Bush, and the cultural elite, led by Barbra Streisand, they are going to side with Mr. Bush, who could come to any suburban barbershop and fit right in.

Most Americans do not have Marxian categories in their heads.

This is the most important reason Americans resist wealth redistribution, the reason that subsumes all others. Americans do not see society as a layer cake, with the rich on top, the middle class beneath them and the working class and underclass at the bottom. They see society as a high school cafeteria, with their community at one table and other communities at other tables. They are pretty sure that their community is the nicest, and filled with the best people, and they have a vague pity for all those poor souls who live in New York City or California and have a lot of money but no true neighbors and no free time.

All of this adds up to a terrain incredibly inhospitable to class-based politics. Every few years a group of millionaire Democratic presidential aspirants pretends to be the people's warriors against the overclass. They look inauthentic, combative rather than unifying. Worst of all, their basic message is not optimistic.

They haven't learned what Franklin and Teddy Roosevelt and even Bill Clinton knew: that you can run against rich people, but only those who have betrayed the ideal of fair competition. You have to be more hopeful and growth-oriented than your opponent, and you cannot imply that we are a nation tragically and permanently divided by income. In the gospel of America, there are no permanent conflicts.


David Brooks, a senior editor at The Weekly Standard, is author of ''Bobos in Paradise: The New Upper Class and How They Got There.''

Wednesday, November 20, 2002

The lucky duckies who pay no income taxes

According to the November 20, 2002 Wall Street Journal editorial "The Non-Taxpaying Class: Those lucky duckies":
The stars look to be in perfect alignment for tax relief. With a GOP majority in both houses of Congress, the Bush Administration is making eager and energetic noises, and the economy is in what Fed Chairman Greenspan calls a soft spot.

But as the Republicans construct their tax plan, there is a large and under-appreciated fact they would do well to keep in mind. Over the past decade or so, fewer and fewer Americans have been paying income taxes and still fewer have been paying a significant percentage of income in taxes. While we would opt for a perfect world in which everybody paid far less in taxes, our increasingly two-tiered tax system is undermining the political consensus for cutting taxes at all.

Even the barest of glances at tax data reveal a system that is steeply progressive. Tax revenue has been increasingly squeezed out of top earners. According to the most recent data, from 1999, the richest--with income above half a million dollars--constituted 0.5% of taxpayers but accounted for 28% of total tax revenue. Simply put, a tiny group of people (553,380) were responsible for more than one-quarter of the income tax take of $877 billion.

...

Well, maybe you're saying--so what? They can afford it. Then take a look at those who aren't Richie Rich. The most recent data from the IRS, in 2000, show that the top 5% coughed up more than half of total tax revenue. Specifically, we are talking about folks with adjusted gross incomes of $128,336 and higher being responsible for 56% of the tax take. Eyebrows raised? There's more. The top 50% of taxpayers accounted for almost all income tax revenue--96% of the total take.

These numbers are more arresting when compared with the situation 14 years earlier. In 1986, the top 1% paid 26% of revenue, the top 5% was responsible for 42% and the top half contributed 93%. And what about the bottom half of taxpayers? They accounted for 7% of the total in 1986 but only 4% in 2000.

This skewed reality is the result of a growing number of absolutely legal escape hatches. Consider what happens to those in the lowest bracket. Say a person earns $12,000. After subtracting the personal exemption, the standard deduction and assuming no tax credits, then applying the 10% rate of the lowest bracket, the person ends up paying a little less than 4% of income in taxes. It ain't peanuts, but not enough to get his or her blood boiling with tax rage.

Of course, lower-income workers are on the hook for the payroll tax--but a sizable group slip free from even that net tax liability via the refundable earned income tax credit. ("Refundable" means that even if your net income tax liability is zero, the government still writes you a check.)

These numbers represent only people who have a positive adjusted gross income. In 1999, there were 127 million tax filers, 94.5 million of whom showed an income tax liability. That is, 26% had no liability at all. The actual number of people filing without paying comes to 16 million (after subtracting those getting earned income tax credits and thus, presumably, still somewhat sensitive to tax rates). So almost 13% of all workers have no tax liability and so are indifferent to income tax rates. And that doesn't include another 16.5 million who have some income but don't file at all.

Who are these lucky duckies? They are the beneficiaries of tax policies that have expanded the personal exemption and standard deduction and targeted certain voter groups by introducing a welter of tax credits for things like child care and education. When these escape hatches are figured against income, the result is either a zero liability or a liability that represents a tiny percentage of income. The 1986 tax reform, for example, with its giant increase in the personal exemption and standard deduction, took six to seven million people off the tax rolls.

...

This complicated system of progressivity and targeted rewards is creating a nation of two different tax-paying classes: those who pay a lot and those who pay very little. And as fewer and fewer people are responsible for paying more and more of all taxes, the constituency for tax cutting, much less for tax reform, is eroding. Workers who pay little or no taxes can hardly be expected to care about tax relief for everybody else. They are also that much more detached from recognizing the costs of government.

All of which suggests that the last thing the White House should do now is come up with more exemptions, deductions and credits that will shrink the tax-paying population even further.

Tuesday, May 1, 2001

A Tale of Two Tax Cuts: What recent history teaches about recessions and economic policy

A Tale of Two Tax Cuts: What recent history teaches about recessions and economic policy

(EPI Issue Brief #157) May 1, 2001

by Michael A. Meeropol

As slow growth continues in the U.S. economy, one of the questions policy makers are asking is whether tax cuts can be used to stave off a recession and, if so, how. The Bush Administration claims that its tax cut proposal (conceived over a year ago) is the best bulwark against an economic slowdown. Since supporters of such tax cuts often invoke historical precedent, such as the fiscal policies of past presidents, it is worth looking at previous attempts to mitigate recessions through tax policy. A close comparison of other attempts to fight recessions with tax cuts-one enacted by President Gerald Ford in 1975 and the other by President Ronald Reagan in 1981-shows that approaches that promote increased consumption by middle- and lower-income families have provided the biggest boosts to flagging economies.

Present-day Republicans, however, are promoting a tax cut that disproportionately benefits those with high incomes, the rationale being that this will stimulate the economy by increasing saving and investment. Critics of these cuts prefer smaller overall tax cuts with greater focus on relief for lower-income individuals; it is these lower- and middle-income families, critics argue, that are most likely to spend any extra disposable income and hence stimulate the economy. A look at recent history supports such claims.

Two major recent recessions-1974-75 and 1981-82-were accompanied by Republican-led tax cuts markedly different from one another both in terms of who benefited and in their long- vs. short-run focus. President Ford's tax cut in 1975 was targeted at low- and moderate-income families and helped to stimulate private consumption, putting the economy back on its feet. By comparison, President Reagan's tax cut in 1981 disproportionately benefited those at the top of the income scale and ultimately did nothing for the slumping economy until 1983.1

Ford's winning strategy (1974-75)
In 1974, the United States economy fell into a deep recession. Unemployment rose from 4.8% in the fourth quarter of 1973 to 8.9 % in the second quarter of 1975. For over five quarters (from the end of 1973 through March 1975) real GDP per capita fell at an annual rate of 3.8%.2 In response, President Ford proposed a significant tax cut in early 1975, which Congress passed by March of that year.

President Ford's tax cut was clearly focused on increasing consumption. Marginal rates were not cut, and instead all taxpayers and their dependents received a credit of $30 (almost $100 in current dollars). In addition, the standard deduction was increased, and a refundable earned income tax credit was enacted. As a result, some beneficiaries of the 1975 tax cut carried no liability for federal individual income taxes.3

The federal budget was nearly balanced in 1974, with a deficit of less than 1% of GDP. That deficit, however, jumped to 3.4% of GDP in fiscal year 1975 and 4.3% in the following year.4 It is clear that the 1975 tax cut, plus some increased spending in the form of extended unemployment compensation benefits, helped raise the federal deficit and increase aggregate demand. As a consequence, this deficit increase was temporary; both deficits and debt as a share of GDP fell at the close of the 1970s.

Much of Ford's stimulus was provided by an expansion in government expenditure, both on the refundable portion of the earned income tax credit and on some extensive expansions of unemployment compensation eligibility. Even though unemployment rose dramatically in 1974, the enactment of new legislation ensured that a higher percentage of the unemployed actually received compensation in 1975 than at any other time between 1967 and today. The high point was reached in April of that year, when 81% of all unemployed workers received compensation. Even as the economy recovered in 1976, the percentage of the unemployed receiving compensation averaged 67%, in marked contrast to both previous and subsequent rates. In fact, between 1967 and 1999, the 1975-77 period is the only three-year period when coverage exceeded 52%.5

Tax and spending changes in 1975 were designed as the first steps toward countering the 1974-75 recession and were heavily weighted toward increasing the disposable income and consumption of moderate- and low-income persons. Ironically, Alan Greenspan led President Ford's Council of Economic Advisers, which was responsible for developing this tax plan.

The results of the plan were striking. First of all, consumption as a percentage of GDP rose from an average of 61.7% in 1974 to 63.1% in 1975. It stayed at that higher level through 1979. Consumption as a percentage of disposable personal income rose from an average of 88.3% in 1974 to over 90% in 1976 through the end of the decade.6 Meanwhile, investment as a percentage of GDP was lower in 1975 than it had been in 1974. It did not recover to the 1973 level until 1977.7 In other words, as with most recession recoveries, consumption increases led and investment increases lagged. The lesson to be learned is that successful counter-cyclical fiscal policy requires tax and spending changes that specifically target increased consumption. President Ford's stimulus package did just that by targeting the low- and moderate-income families most likely to spend any extra income.

After establishing this strategy, monetary policy was then designed to support the president's efforts to stimulate the economy. Nominal interest rates fell throughout 1974, and when they began to rise in early 1975, the recovery was already well under way.8

President Ford's exercise of counter-cyclical fiscal policy worked. A recovery began in the second quarter of 1975. Real GDP per capita had been negative for all of 1974 and was falling at an annual rate of 6.7% in the first quarter of 1975. For the final three quarters of 1975, beginning with the quarter when the temporary tax cuts went into effect, the rate of growth of real GDP averaged over 4%. The rate of growth for 1976 was 3.8%. The unemployment rate fell to 7.7% in 1976 and continued to fall for the rest of the decade.9

The Reagan experiment (1981-83)
In 1981, before the recession had begun, President Reagan convinced Congress to accept a three-year tax cut. He did not justify his proposal as a way of combating recession but claimed instead that it would stimulate the "supply side" of the economy by enhancing incentives to work, save, and invest. The tax cut was heavily weighted toward reducing the tax burden of higher-income taxpayers and corporations. Its impact was also delayed-very little of the cuts actually took effect in 1981.10

A recession began in the fourth quarter of 1981, as unemployment rose from 7.4% to 8.2%. By the fourth quarter of 1982, the unemployment rate peaked at 10.7%. Between October 1981 and December 1982, the shrinkage in per capita GDP averaged 3.4% in annual terms.11 In 1981 the economy needed a stimulus, just as in 1974-75, but this time none was provided. In fact, the federal deficit as a percentage of GDP actually declined in 1981, due to increased revenues resulting from "bracket creep" in the individual income tax and from scheduled increases in the payroll tax for Social Security. Nor was any extension of unemployment benefits passed.

The tax cuts of 1981 brought significant reductions in income tax collections at the high end of the income spectrum and a dramatic reduction in corporate taxes. However, the impact on consumption was virtually nonexistent. In 1982-the first year of 10% rate cuts-the federal budget deficit rose dramatically. Consumption as a percentage of GDP rose in 1982, but investment fell so much that the overall increase in aggregate demand was insufficient to lift the economy out of its recession. The recession lingered through the fourth quarter of 1982 and the unemployment rate continued to rise, reaching its 10.7% peak in the fourth quarter, just when the business cycle was in its trough.

Relative to 1975, the recession did not last much longer. It did, however, do much more damage to the economy because it was so much deeper. Unemployment was above 8% for only four quarters during the 1974-75 recession, with the peak coming in the second quarter of 1975 at 8.9%. In 1981-83, unemployment was above 8% for a full seven quarters, stretching all the way into the first four quarters of the recovery. (It is also worth noting that monetary policy may have been less expansive in 1982 than in 1975 and 1976.)12

Even though Reagan's tax cut was passed before the recession of 1981 began, its impact wasn't even felt until 1983 when the recovery had already begun. That same year, the federal deficit as a percentage of GDP reached 6.1%, as the second of the 10% tax cuts went into effect. So, although 1983 saw growth in real GDP, unemployment was almost as high in 1983 as in 1982, despite a continued increase in the level of consumption relative to GDP. A policy change that might have stimulated even more consumption, such as the passage of extended unemployment benefits, did not occur in 1981. The percentage of unemployed actually receiving benefits averaged only 45% in 1982 and 44% in 1983, far less than the rates in the 1975-77 period.13

Lessons learned
The experience of the 1981-83 recession contrasts sharply with the policy changes made in response to the 1975 recession. The main differences were that:

the Reagan tax cut was backloaded. It had its greatest impact in fiscal year 1983 (federal tax revenue actually declined in that year).

the Reagan tax cut was not focused on the lower- and middle-income workers whose consumption must rise in order to begin the process of recovery. It also was not combined with significant expansion of transfer payments in the form of unemployment compensation, as Ford's tax cut was.

Consumption is the main driving force that can get the economy out of a slump. Investors are notoriously conservative. Once they get spooked by a recession, they usually wait for consumption to rise again before committing to new investment projects. Investment as a percentage of GDP usually doesn't rise until long after a recovery is underway. The past tax cuts show that Ford's cut induced an investment recovery within one year, while the Reagan tax cut failed to induce any recovery for almost two.

The parallels between President Bush's proposal and Reagan's earlier failure are indisputable. Like Reagan, Bush's plan was designed well before the current signs of economic slowdown. And as in 1981, Bush's plan tries to sell the merits of supply-side doctrine that incentives can be improved by reducing marginal tax rates for those subject to income tax. But the Bush proposal goes even further than Reagan's-Bush's cuts are even more concentrated on higher-income families and are even more extremely backloaded.

As recent history makes clear, backloaded tax cuts delay the impact on aggregate demand and mute efforts to fight recessions. And tax cuts that neglect the individuals most likely to spend extra income do not work well when the goal is to combat a recession. A large share of any stimulus should be focused on low- and moderate-income families. To this end, a plan along the lines of the recently proposed "prosperity dividend" -a proposal to issue each taxpayer a one-time rebate of around $500 drawn from the federal budget surpluses-would raise aggregate demand and have the best chance of heading off any imminent recession.14

Endnotes
1. For details of the Ford plan, see Economic Report of the President (1976, 50-57). For details of the Reagan plan and its impact, see Michael Meeropol's Surrender: How the Clinton Administration Completed the Reagan Revolution (1998, 79-81, 91-92).

2. See the web page for Surrender (Meeropol 1998) at http://mars.wnec.edu/~econ/surrender/. The unemployment rate and rate of growth of per capita real GDP data are in Table W.4 found on that web page.

3. See Economic Report of the President, 1976, p. 51.

4. See Economic Report of the President, 1998, p. 373.

5. For data on the percentage of the unemployed receiving compensation from 1967 to 1999, see Committee on Ways and Means, U.S. House of Representatives 2000, Green Book, pp. 284-5.

6. See http://mars.wnec.edu/~econ/surrender/ Table W.5.

7. For investment as a percentage of GDP, see Table W. 4 at http://mars.wnec.edu/~econ/surrender/.

8. For the nominal federal funds rate, see Table W. 2. For the nominal prime rate, see Table W.3.

9. For the nominal federal funds rate, see Table W. 2. For the nominal prime rate see Table W.3.

10. See Table W.4.

11. See Surrender, pp. 79-81.

12. For data on consumption as a percentage of GDP, see Table W.5 at http://mars.wnec.edu/~econ/surrender/. For data on investment, unemployment, and the rate of growth of real GDP, see Table W.4. For data on the federal budget deficit, see Economic Report of the President (1998, p. 373). For the rate of growth of the money supply and the nominal and real federal funds rate, see Table W. 1.

13. For data on coverage of unemployment compensation, see Green Book, op cit. For data on consumption, see Table W.5. For data on investment and the rate of growth, see Table W.4.

14. For more details on the prosperity dividend proposal, see EPI's reports Declare a Prosperity Dividend: A Stimulating Idea for the U.S. Economy (2001) and The Case for a Prosperity Dividend (2001) by Eileen Appelbaum and Richard B. Freeman.

Sunday, April 8, 2001

Talk of Lost Farms Reflects Muddle of Estate Tax Debate

In the April 8, 2001 New York Times article "Talk of Lost Farms Reflects Muddle of Estate Tax Debate," David Cay Johnston explains that the risk of family farms being lost because of the estate tax has been exaggerated by some advocates of the tax's elimination.
Correction Appended

Harlyn Riekena worried that his success would cost him when he died. Thirty-seven years ago he quit teaching to farm and over the years bought more and more of the rich black soil here in central Iowa. Now he and his wife, Karen, own 950 gently rolling acres planted in soybeans and corn.

The farmland alone is worth more than $2.5 million, and so Mr. Riekena, 61, fretted that estate taxes would take a big chunk of his three grown daughters' inheritance.

That might seem a reasonable assumption, what with all the talk in Washington about the need to repeal the estate tax to save the family farm. ''To keep farms in the family, we are going to get rid of the death tax,'' President Bush vowed a month ago; he and many others have made the point repeatedly.

But in fact the Riekenas will owe nothing in estate taxes. Almost no working farmers do, according to data from an Internal Revenue Service analysis of 1999 returns that has not yet been published.

Neil Harl, an Iowa State University economist whose tax advice has made him a household name among Midwest farmers, said he had searched far and wide but had never found a case in which a farm was lost because of estate taxes. ''It's a myth,'' Mr. Harl said.

Even one of the leading advocates for repeal of estate taxes, the American Farm Bureau Federation, said it could not cite a single example of a farm lost because of estate taxes.

The estate tax does, of course, have a bite. But the reality of that bite is different from the mythology, in which family farmers have become icons for the campaign to abolish the tax. In fact, the overwhelming majority of beneficiaries are the heirs of people who made their fortunes through their businesses and investments in securities and real estate.

The effort to end the estate tax -- which critics call the death tax -- gained ground when the House of Representatives voted Wednesday to reduce the tax and then abolish it in 2011. The bill faces an uncertain fate in the Senate.

The estate tax is central in the debate over taxes, not only because the sums involved are huge but also because to both sides it is a touchstone of national values. To those seeking to abolish it, the estate tax is a penalty for success, an abomination that blocks the deeply human desire to leave a life's work as a legacy for the children. It is also a complicated burden that enriches the lawyers, accountants and life insurance companies that help people reduce their tax bills.

To its supporters, on the other hand, the estate tax is a symbol of American equality, a mechanism to democratize society and to encourage economic success based on merit rather than birthright.

Yet for all the passion in the debate, the estate tax does not always seem broadly understood.

While 17 percent of Americans in a recent Gallup survey think they will owe estate taxes, in fact only the richest 2 percent of Americans do. That amounted to 49,870 Americans in 1999. And nearly half the estate tax is paid by the 3,000 or so people who each year leave taxable estates of more than $5 million.

In fact, the primary beneficiaries of the move to abolish the estate tax look less like the Riekenas and more like Frank A. Blethen, a Seattle newspaper publisher whose family owns eight newspapers worth perhaps a billion dollars.

''Being ever bloodthirsty, the I.R.S. will start with the highest value it can on my estate,'' said Mr. Blethen, the 55-year-old patriarch of the publishing family. The figure for his share will probably be several hundred million dollars, more than half of which would go to the government. Mr. Blethen is trying to avoid almost all those taxes through a plan also used by other wealthy families, but if he does not succeed his sons' interest in the business will be wiped out, he said.

Estate taxes are paid by few Americans because they are not assessed on the first $1.35 million of net worth left by a couple. Amounts above this are taxed at rates that begin at 43 percent and rise to 55 percent on amounts greater than $3 million. As the Riekenas and the Blethens have learned, there are many legal ways to reduce the value of one's wealth for estate tax purposes. So even for the largest estates, the tax averages 25 percent.

Family farmers are often cited as victims. As Senator Charles E. Grassley, an Iowa hog farmer and chairman of the Senate Finance Committee, put it, ''The product of a life's work leaches away like seeds in poor soil.''

Yet tax return data show that very few farmers pay estate taxes. Only 6,216 taxable estates in 1999 included any agricultural land and equipment, the I.R.S. report shows. The average value of these farm assets was $440,000, only about a third of the amount that any married couple could leave untaxed to heirs. What is more, a farm couple can pass $4.1 million untaxed, so long as the heirs continue farming for 10 years.

In Iowa, the average farm has a net worth of $1.2 million. Loyd A. Brown, president of Hertz Farm Management in Nevada, Iowa, which runs more than 400 farms in 10 states, said none of his firm's clients nor anyone he knew was facing problems because of the estate tax.

Just 1,222 estates in 1999 had enough in farm assets to make the farm property alone subject to estate taxes. But these farm assets amounted to one-tenth of these estates, suggesting that the tax applies mostly to gentleman farmers and ranchers, rather than to working farmers like the Riekenas, whose fortunes are tied up in their farms.

As the Riekenas were surprised to discover, avoiding the estate tax was easy. Their lawyer developed a simple plan that involved making gifts to their daughters and buying life insurance to offset any estate taxes that might be due if the parents died before most of the farm had been turned over to their daughters.

There is a real cost, of course -- payments to the lawyer and for the insurance. And in any case the paucity of affected farmers does not end the debate. Patricia A. Wolff, the Farm Bureau's chief lobbyist, said the organization made estate tax repeal its top priority because, while it has not surveyed its members, she was confident ''the majority of farmers and ranchers believe that death taxes are wrong and that it is wrong to tax people twice on what they earn.''

But Mr. Riekena and all two dozen other farmers interviewed across central Iowa -- every one a Republican -- said that while they favored increasing the amount that could be passed to heirs untaxed, they did not support the repeal proposed by President Bush and other leaders of his party. A few snickered or laughed when asked whether the estate tax should be repealed to save the family farm.

But Senator Grassley himself opposes the estate tax, in large part because he thinks that while a decision to keep or sell an asset is an appropriate trigger for a tax, death should not be.

He added another reason: ''I do not think that the function of government is to redistribute wealth.''

Indeed, that seems to be the fault line in the debate: should the government play Robin Hood with estates?

''If you worked hard and put your money away, you paid tax on it as you went along, so it's yours and you should be able to pass it on to your children without the government penalizing you,'' said R. Elaine Gunland, who grows grapes in Fresno, Calif., and whose family may owe estate taxes when she dies.

Mr. Blethen, the fourth-generation publisher of a newspaper started in 1896 with $3,000, says he speaks for many others in supporting repeal of the tax in the name of preserving family businesses.

''I firmly believe that family-owned businesses are the heart and soul of the country,'' said Mr. Blethen, who has created a Web site called deathtax.com.

Mr. Blethen says the estate tax benefits publicly traded companies at the expense of family-owned businesses. The reason is that the public companies can often buy family businesses at a discount because the owners did not raise the cash to pay estate taxes and must sell quickly at fire sale prices.

Mr. Blethen said some of the seven smaller papers his family bought in Washington and Maine came from families that had not planned carefully for the estate tax and decided it was easier to cash out.

''If you like corporate culture, and think America needs more of it, then you love the estate tax,'' he said. ''I think this march toward corporatism is not healthy and we lose innovation, jobs and charitable giving.''

Mr. Blethen said the estate tax also discouraged major new investments in family businesses late in the life of the primary owner because such investments consumed cash that might be needed at any time to pay estate taxes.

He said the estate tax also ''forces you into irresponsible gift making'' to heirs. He felt compelled to give half the future growth of his fortune to his two sons when they were not yet kindergartners even though he had no way of telling whether the boys would turn out to be industrious, as they did, or scalawags.

Despite his fierce opposition to the estate tax, Mr. Blethen does not support President Bush's current plan to repeal the tax because it would also exempt from capital gains taxes the profits on assets passed to heirs when those assets are sold. ''That's not fair,'' Mr. Blethen said.

He said Mr. Bush's proposal would have the perverse effect of encouraging the sale of family-owned businesses, because heirs would see death as their chance to sell tax-free and to diversify their portfolios, instead of continuing to bear the risks of holding a single enterprise.

Mr. Blethen thinks that rather than taxing an estate, taxes should apply when a business is sold. ''You want to defer those capital gains and let them grow so large that the family will keep the business to avoid the capital gains taxes,'' he said.

The debate does not divide neatly among rich and poor. Since February more than 800 wealthy Americans have joined in a public appeal to keep the estate tax. They argue that repealing the tax would further enrich the wealthiest Americans and hurt struggling families. They also argue that financial success should be based on merit rather than on inheritance.

Warren E. Buffett, George Soros, Paul Newman and William H. Gates Sr., father of Microsoft's chairman, William H. Gates III, are among the most prominent in that group, which also includes many people with holdings of just a million dollars.

Mr. Buffett said the estate tax fosters economic growth by encouraging Americans to rise based on merit, not inheritance. ''If you take the C.E.O.'s of the Fortune 500,'' he said in an interview, ''and put in the eldest son of every one of those who ran the place in 1975, the American economy would not run as well as letting the Jack Welches, who started out with nothing, rise to the top of General Electric.''

Back in central Iowa, Mr. Riekena had another reason. He said Washington was focused on the wrong issue when it came to saving family farms.

''For most farmers around here, the estate tax is not high in their minds,'' Mr. Riekena said. ''What we need are better crop prices.''

Photos: Harlyn Riekena, who owns 950 acres of farmland in Iowa, expects to owe nothing in estate taxes. (Suzanne DeChillo/The New York Times)(pg. 1); Frank A. Blethen, publisher of The Seattle Times, says the estate tax could cost his family many millions of dollars after his death. (Peter Yates for The New York Times)(pg. 24) Chart: ''Few Farms in Taxable Estates'' Estate tax opponents say the levy is destroying the family farm. But only the richest 2 percent of the 2.4 million Americans who died in 1999 left estate tax bills. Only one in eight of these taxable estates included any farm property. On average, only one in 40 taxable estates included enough farm land and equipment for the farm asssets alone to incur estate taxes. 49,870: Total number of taxable estates in 1999 6,216, or 12.5 percent, of the taxable estates had any farm assets 1,222, or 2.5 percent of estates, on average, might have had to pay taxes because of their farm assets. (Source: Internal Revenue Service)(pg. 24)

Correction: April 12, 2001, Thursday A front-page article on Sunday about farms and estate taxes referred incompletely to the position of Loyd A. Brown, president of Hertz Farm Management in Iowa. Mr. Brown said that while he did not know of anyone who had lost a farm because of the estate tax, he thought Congress should either eliminate the tax or increase the amount that could be inherited untaxed.